Although antibodies against these molecules are already approved therapies for various types of cancer, several antibodies and small molecules are currently under development that target other immune checkpoints such as Lymphocyte Activation Gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin mucin-3 (TIM3), B7 homolog 3 protein (B7H3), CD39, CD73, adenosine A2A and CD47 [77]. This evidence concerns the gene HAVCR2 and cancer.